Generic Medicine Info
May be taken with or without food.
Women. Children. Pregnancy and lactation.
Special Precautions
Patient with large residual urine and/or severely decreased urinary flow. Not indicated for the prevention of prostate cancer. Hepatic impairment. Patient Counselling Women of child-bearing potential or who are pregnant should not handle crushed or broken tab. Excreted in semen therefore use of condom is recommended. Monitoring Parameters Rule out other urological diseases (e.g. prostate cancer) before initiation of therapy. Perform digital rectal examination and other assessment for prostate cancer before and during therapy. Obtain new baseline prostate-specific antigen (PSA) level after ≥6 months of treatment then monitor periodically thereafter. Monitor for psychiatric symptoms, objective and subjective signs of relief of benign prostatic hyperplasia (e.g. improvement in urinary flow, reduction in symptoms of urgency, relief of difficulty in micturition).
Adverse Reactions
Significant: Breast cancer, mood alterations (e.g. depressed mood, depression and rarely, suicidal ideation). Immune system disorders: Hypersensitivity reaction (e.g. angioedema, urticaria). Investigations: Decreased volume of ejaculate. Reproductive system and breast disorders: Impotence, decreased libido, ejaculation disorder, haematospermia, breast tenderness and enlargement, testicular pain, male infertility and/or poor seminal quality. Skin and subcutaneous tissue disorders: Rash, pruritus.
ATC Classification
D11AX10 - finasteride ; Belongs to the class of other dermatologicals.
G04CB01 - finasteride ; Belongs to the class of testosterone-5-alpha reductase inhibitors. Used in the treatment of benign prostatic hypertrophy.
Disclaimer: This information is independently developed by CIMS based on finasteride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in